July 14, 2006
Volume 34
Issue 28
search only SGN online
Saturday, May 30, 2020



New HIV once daily regimen will simply dosing of HIV therapy, says organization for people with HIV/AIDS
New HIV once daily regimen will simply dosing of HIV therapy, says organization for people with HIV/AIDS
"This is a monumental accomplishment," said Frank Oldham, Jr., NAPWA's Executive Director.

The National Association of People with AIDS (NAPWA-US) applauds the U.S. FDA for approving Atripla the Bristol-Myers Squibb and Gilead Sciences' Once Daily Single Tablet Regimen of Sustiva(R) (Efavirenz) and Truvada(R) (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Treatment

On behalf over one million Americans living with HIV and the 40 million people living with HIV globally NAPWA commends the partnership between Bristol-Myers Squibb and Gilead Sciences founded on a shared commitment to addressing the needs of people living with HIV. Significant progress in science and medicine has been achieved since the advent of the first combination regimens 10 years ago, but more work is needed and we view this partnership that has produced Atripla-the first-ever once-daily single tablet regimen for HIV as an important step toward further simplifying dosing of HIV therapy for physicians and patients. NAPWA is extremely delighted with the approval of this simple regimen.

This new single tablet regimen is the first and only product that contains a complete Highly Active Antiretroviral Therapy (HAART) regimen in a single once-daily tablet, intended for the treatment of HIV-1 infection in adults as a complete regimen or in combination with other antiretroviral. Today's fast track approval of Atripla marks significant progress of the FDA to quickly deliver quality, life-saving HIV/AIDS drugs to people who desperately need them. This new once-a-day single tablet HIV medication may significantly assist an individuals' ability to adhere to their HIV treatment regimen and reduce the potential for viral resistance. NAPWA is hopeful governmental and industry leaders will afford access to this new HIV treatment to benefit over One million HIV positive Americans and the Forty million HIV positive people across the globe that urgently require access to life-saving HIV/AIDS drugs.

"This is a monumental accomplishment," states Frank Oldham, Jr., NAPWA's Executive Director. "On behalf of the one million Americans living with AIDS we are grateful to our partners in the scientific community for their research and development of Atripla. We know that approximately 250,000 Americans do not know that they are HIV positive. We must now work diligently in partnership with CDC and HRSA to get more people tested for HIV, into care as early as possible, to reduce AIDS Stigma and other barriers to accessing quality HIV care and treatment. While this news is very encouraging we must remember the AIDS crisis in America and throughout the world is far from over."

Founded in 1983, the National Association of People with AIDS (NAPWA-US) is a non-profit membership organization that advocates on behalf of all people living with HIV and AIDS in order to end the pandemic and the human suffering it causes. NAPWA has several initiatives designed to promote access to and the utilization of HIV prevention and treatment, and to reduce stigma towards HIV-positive people.

A NAPWA press release

International Readers
We want to learn about you and have you tell us about Gay Life where you live.
Please click here

Seattle Gay Blog
It's new!
A blog created
by the SGN staff
so you can be heard

working for the freedom to
marry since 1995

copyright Seattle Gay News - DigitalTeamWorks 2006